Urogen Pharma Ltd
NASDAQ:URGN

Watchlist Manager
Urogen Pharma Ltd Logo
Urogen Pharma Ltd
NASDAQ:URGN
Watchlist
Price: 22.98 USD -5.35% Market Closed
Market Cap: 1.1B USD

P/E
Price to Earnings

-6.5
Current
-4.1
Median
24
Industry
Lower than median
Lower than industry value

The Price to Earnings (P/E) ratio shows how much investors are willing to pay for each dollar of a company’s earnings. It’s calculated by dividing the company’s market value by its net income.

P/E
-6.5
=
Market Cap
1.1B USD
/
Net Income
-164.6m USD
All Countries
Close
Earnings Growth PEG
IL
Urogen Pharma Ltd
NASDAQ:URGN
Average P/E: 213
Negative Multiple: -6.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 938.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
170.2
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.3
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
9%
1.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 385.9
N/A N/A
AU
CSL Ltd
ASX:CSL
19.9
11%
1.8
NL
argenx SE
XBRU:ARGX
36.4
40%
0.9

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-7.1
2-Years Forward
P/E
-31.1
3-Years Forward
P/E
15.7